Does Finasteride Carry a Higher Risk of Depression Than Dutasteride?
Published by AmpleLab Research
A specific pattern gets reported often enough to be worth taking seriously: people who report developing low mood, anhedonia, or depressive symptoms on finasteride, then switch to dutasteride and feel fine, despite dutasteride suppressing DHT more completely and inhibiting a second enzyme finasteride leaves alone. Mechanistically, that's genuinely puzzling rather than obviously explicable, and it gets more puzzling, not less, once you look at which enzyme is actually active in the brain.
This article covers what's actually known specifically about mood and depression: a real anatomical detail that complicates the obvious explanation, what large pharmacovigilance databases show, what more structured cohort studies show (which don't fully agree with each other), and why that disagreement itself is informative. For why the two drugs can differ on other side effects entirely, not just mood, see our article on individual variation in finasteride and dutasteride side effects, which covers the pharmacogenetics of the enzyme itself rather than population-level mood data.
The Detail That Makes This Genuinely Puzzling
Finasteride selectively inhibits type II 5-alpha reductase (SRD5A2); dutasteride inhibits both type I (SRD5A1) and type II. The natural assumption is that dutasteride, blocking more of the same general pathway, should carry at least as much potential for DHT-related neuropsychiatric effects. A recent systematic review complicates that assumption directly.
A PRISMA-guided systematic review of 83 studies on 5-alpha reductase tissue distribution and mental health outcomes. Its finding on distribution is the key detail: type I (SRD5A1), the isoform dutasteride additionally inhibits, is "widely expressed in the liver, skin, and, most notably, CNS, including the cerebral cortex and cerebellum." Type II, finasteride's selective target, is comparatively minor in brain tissue by contrast, with its best-characterised roles in the prostate, skin, and hair follicles.
If type I is the predominant CNS-relevant isoform, the naive prediction runs backwards from what the anecdotal pattern describes: dutasteride, by inhibiting the enzyme most broadly expressed in brain tissue, might be expected to have at least as much potential to disrupt brain neurosteroid synthesis (including allopregnanolone, a GABA-A positive modulator with mood-relevant effects) as finasteride. That doesn't mean the anecdotal pattern is wrong. It means the simple "more enzymes blocked equals more brain risk" explanation doesn't hold up on its own.
What Large-Scale Pharmacovigilance Data Shows
Using a global pharmacovigilance database of over 35 million adverse event reports from 140+ countries (1992-2024), this study found a signal for depression with finasteride (reporting odds ratio 28.18, 95% CI 26.57-29.89) roughly nine times stronger than the signal for dutasteride (ROR 3.23, 95% CI 2.61-4.00). For suicidality, finasteride showed a significant signal (ROR 7.28, 95% CI 6.57-8.06) while dutasteride showed none. The strongest signals were concentrated in younger men (18-44) using low-dose therapy, the population that best matches typical AGA users rather than older BPH patients.
The roughly nine-fold difference is a difference in disproportionality signals within a spontaneous-reporting database, not a measured difference in how often people taking each drug actually develop depression. It is not evidence that people taking finasteride are nine times more likely to develop depression than people taking dutasteride.
This is a striking, large difference in reported signal strength. It's also, by design, a study of spontaneous adverse event reports, meaning it captures who reported what to a regulatory database, not a controlled comparison of who actually experienced what. The authors themselves note that causality cannot be inferred from this kind of data, and call for further epidemiological studies to clarify the clinical significance of the signal. Reporting rates are shaped by awareness: finasteride's association with mood and sexual side effects, under the banner "post-finasteride syndrome," has been a prominent, widely discussed topic in patient communities and regulatory communications for over a decade. Dutasteride has received comparatively little of that attention. A person already primed to watch for and attribute symptoms to finasteride specifically is more likely to notice, report, and label them than someone on a drug without that same cultural narrative attached, independent of whether the underlying biological risk actually differs.
What Structured Cohort Studies Show, and Why They Disagree
Studies that track a defined population forward in time, rather than relying on who chooses to file a report, tell a less clear-cut story.
A Korean nationwide cohort of 51,466 men aged 60 or older, followed for 7 years, found no significant increase in completed suicide among 5-alpha reductase inhibitor users versus non-users overall, and no significant difference by drug type.
A Swedish register-based cohort of over 2.2 million men found both finasteride and dutasteride were associated with an increased risk of depression, without reporting a meaningful difference between the two drugs. No association was found with suicide for either.
Neither cohort study reproduces the roughly nine-fold gap the pharmacovigilance data showed. This isn't necessarily a contradiction so much as a mismatch in what each method can see. Both cohort studies were built around older populations, generally men in their 60s or being treated for benign prostatic hyperplasia, not the younger men using low-dose finasteride for hair loss, which is specifically where the pharmacovigilance signal was strongest. Cohort studies also can't fully capture symptoms that are noticed, attributed, and never formally reported to a doctor as a suspected drug reaction, which spontaneous reporting databases (imperfectly) can. Different methods, looking at different populations, answering subtly different questions, arriving at different-looking answers. That's a genuine limitation of the current evidence, not something either side of it should be quietly dropped to make the picture tidier.
A Non-Neurosteroid Mechanism Worth Knowing About
One further candidate explanation involves a different downstream consequence of reduced DHT, hippocampal neurogenesis rather than neurosteroid/GABA signalling specifically, tested directly in animals rather than inferred from tissue distribution.
In male mice, seven days of finasteride treatment reduced brain DHT and produced a reversible reduction in newborn cells and young neurons in the hippocampus. The authors proposed that this alteration in neuronal plasticity could be relevant to the pathophysiology of depression. This is rodent data, not human evidence, and it did not include a head-to-head dutasteride comparison, so it can't establish whether the effect is specific to finasteride or shared by 5-alpha reductase inhibition more generally.
Where This Actually Leaves the Answer
The Honest Position
The simple story, that dutasteride blocks more enzyme so should carry equal or greater neuropsychiatric risk, doesn't survive contact with the actual tissue distribution data; type I, dutasteride's additional target, is the isoform most broadly expressed in the brain. None of this proves that any specific individual's depression on finasteride was caused by the drug, or that switching to dutasteride will resolve it for any given person. What it does establish is that the pattern is detectable at a population level in spontaneous-reporting data, with a large, if imperfect, difference in reported signal strength between the two drugs.
The current evidence therefore doesn't establish that finasteride causes depression more often than dutasteride. It does show a striking finasteride-specific signal in global spontaneous-reporting data, while structured cohort studies have not reproduced a clear difference between the drugs. The biological evidence adds a genuine complication to the simple DHT explanation, but doesn't yet tell us which mechanism, if any, accounts for the epidemiological pattern.
Anyone experiencing new or worsening depressive symptoms, anxiety, or thoughts of self-harm while taking either drug should raise it with their prescriber promptly rather than waiting to see if it resolves; this is explicitly one of the circumstances where continued use should be reevaluated, regardless of which specific mechanism turns out to be responsible. Switching from finasteride to dutasteride is a legitimate thing to discuss with a prescriber given the evidence above, not a guaranteed fix, and not something to do unsupervised.
Frequently Asked Questions
Shouldn't dutasteride be worse for mood since it blocks more of the enzyme?
That's the intuitive prediction, and it's complicated by the fact that type I, the additional enzyme dutasteride blocks, is the isoform more broadly expressed in brain tissue, while finasteride's target (type II) is comparatively minor there. The simple "more enzyme blocked, more risk" logic isn't sufficient once you know which isoform is where.
So is finasteride actually worse for depression than dutasteride, or not?
The evidence is genuinely mixed depending on the method. Large spontaneous-reporting pharmacovigilance data shows a much stronger signal for finasteride. Structured cohort studies, mostly in older men, generally haven't found as clear a difference. Both types of evidence have real limitations, and neither fully settles the question on its own.
Could the difference just be that more people talk about finasteride online?
This is a genuinely plausible contributor, not a dismissal of the phenomenon. Finasteride's association with mood and sexual side effects has been a prominent topic in patient communities and regulatory warnings for over a decade; dutasteride hasn't received the same attention. That awareness gap could inflate reporting for finasteride independent of any true difference in underlying risk, and it's consistent with why structured cohort studies, which don't rely on people choosing to report, show a smaller gap.
I'm experiencing low mood on finasteride. What should I do?
Speak to your prescriber promptly rather than waiting it out, particularly if you notice thoughts of self-harm alongside it. This is a recognised reason to reevaluate continued use, and switching to another approach, including dutasteride, is a reasonable option to discuss, but it's a clinical decision, not something to manage alone.
Selected Research
This article is provided for educational purposes and does not constitute medical advice. Finasteride and dutasteride are prescription medications; decisions about starting, stopping, or switching between them should be made with a GP or dermatologist. If you are experiencing thoughts of self-harm or suicide, please contact your GP, NHS 111, or the Samaritans on 116 123. AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition.
AmpleLab.